Table 4.
Clinical efficacy rate | Performance status | Leukopenia | Gastrointestinal side effects | |
---|---|---|---|---|
AD + CT | 46.2% | 63.84% | 53.59% | 53.58% |
CT | 6.84% | 1.55% | 3.86% | 13.58% |
CKS + CT | 72.61% | 65.84% | 90.47% | 56.55% |
EL + CT | 48.14% | NR | NR | 50.78% |
HCS + CT | 59.17% | 26.34% | 24.85% | 48.57% |
KLT + CT | 61.4% | NR | NR | NR |
SF + CT | NR | 88.29% | 68.45% | 68.67% |
SQFZ + CT | 65.83% | 62.17% | 50.28% | 64.95% |
XAP + CT | 39.81% | 41.97% | 58.5% | 43.32% |
AD, Aidi injection; SF, Shenfu injection; SQFZ, Shenqi Fuzheng injection; KLT, Kanglaite injection; EL, elemene injection; XAP, Xiaoaiping injection; CKS, Compound Kushen injection; HCS, Huachansu injection; CT, chemotherapy.